Federal Register #2026-07147

Exclusive Patent License for Catheter-Based Myotomy Devices (SESAME and TAHINI Systems) to Septune, Inc.

This opportunity involves the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH) considering an exclusive patent license grant to Septune, Inc. for advanced catheter-based myotomy devices. - Government Buyer: - National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Department of Health and Human Services - OEMs and Vendors: - Septune, Inc. (prospective exclusive licensee) - Products/Technologies: - Electrosurgical Myotomy Catheter System (SESAME) - Part Number: E19420250US01 - Designed for variable-depth, longitudinal endomyocardial myotomy - Controlled-Depth Myotomy Catheter System (TAHINI) - Part Numbers: E16620220PC01, PCT/US2023/079114, E16620220US02, 19/127,710, E16620220EP01, 23821091.8, E16620220US01, 63/890,784, 63/383,012 - Enables precise, reproducible myotomy procedures - Unique/Notable Requirements: - License is exclusive and worldwide, limited to catheter-based myocardial myotomy systems - Patent rights are assigned to the U.S. Government - No specific product quantities; this is a patent license, not a direct procurement - Intended for treatment of cardiovascular diseases, including hypertrophic cardiomyopathy and facilitating non-surgical mitral valve implantation - Place of Performance: - Septune, Inc., San Juan, Puerto Rico - NHLBI, NIH (federal office) - No direct purchase or delivery; opportunity is for exclusive commercialization rights to government-owned patents

Description

The National Heart, Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is considering granting an exclusive patent license to Septune, Inc. for inventions related to catheter-based myotomy devices and systems. These inventions include controlled-depth myotomy catheter systems designed to perform precise longitudinal endomyocardial myotomy for treating cardiovascular diseases such as hypertrophic cardiomyopathy. The license would cover worldwide rights limited to the field of catheter-based myocardial myotomy systems. Written comments or license applications must be submitted by May 14, 2026.

View original listing